World's Best Scientists 2026 revealed!
Award Badge
Medicine
UK
2023

D-Index & Metrics

Immunology

D-Index
148
Citations
91983
World Ranking
127
National Ranking
13

Medicine

D-Index
149
Citations
92237
World Ranking
1193
National Ranking
126

Research.com Recognitions

  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

Paul P. Tak is affiliated with GlaxoSmithKline in the United Kingdom. Their research spans multiple fields within medicine and molecular biology, with a significant focus on clinical and translational studies.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, their subfields of study are:

  • Oncology
  • Genetics
  • Rheumatology
  • Immunology
  • Pathology and Forensic Medicine

The topics most frequently addressed in their work are:

  • Rheumatoid Arthritis Research and Therapies
  • Virus-based gene therapy research
  • CAR-T cell therapy research
  • Cancer Research and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Lymphoma Diagnosis and Treatment
  • Systemic Lupus Erythematosus Research

Paul P. Tak has contributed publications to several journals and conference programs, with frequent publications in the following venues:

  • Regular and Young Investigator Award Abstracts
  • The Lancet Rheumatology
  • Journal of Clinical Oncology
  • Neuro-Oncology
  • Arthritis Research & Therapy

Recent publications include:

  • "Clinical trial links oncolytic immunoactivation to survival in glioblastoma" (2023, Nature)
  • "A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome" (2022, JCI Insight)
  • "A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis" (2021, BMJ Open Gastroenterology)
  • "A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis" (2021, Arthritis Research & Therapy)
  • "Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study" (2020, Clinical Pharmacology & Therapeutics)

The scientist collaborates frequently with several colleagues, including:

  • Francesca Barone
  • Laura K. Aguilar
  • Andrea G. Manzanera
  • Estuardo Aguilar-Córdova
  • David Krisky

Best Publications

  • 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

    Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits

  • NF-κB: a key role in inflammatory diseases

    Paul P. Tak;Gary S. Firestein

  • Genetics of rheumatoid arthritis contributes to biology and drug discovery

    Yukinori Okada;Yukinori Okada;Di Wu;Di Wu;Di Wu;Gosia Trynka;Gosia Trynka;Towfique Raj;Towfique Raj

  • Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

    Daniel Tracey;Lars Klareskog;Eric H. Sasso;Jochen G. Salfeld

  • Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

    Eli A Stahl;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Gang Xie

  • Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

    Wolfgang Hueber;Dhavalkumar D. Patel;Thaddeus Dryja;Andrew M. Wright

  • Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis

    Frieda A. Koopman;Sangeeta S. Chavan;Sanda Miljko;Simeon Grazio

  • MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins.

    Yuanjia Tang;Xiaobing Luo;Huijuan Cui;Xuming Ni

  • Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

    Geertje M Bartelds;Carla A Wijbrandts;Michael T Nurmohamed;Steven Stapel

  • Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity

    P. P. Tak;T. J. M. Smeets;M. R. Daha;P. M. Kluin

  • Common variants at CD40 and other loci confer risk of rheumatoid arthritis

    Soumya Raychaudhuri;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Annette T Lee;Rachel Hackett

  • Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

    Gerrit Jan Wolbink;Marijn Vis;Willem Lems;Alexandre E. Voskuyl

  • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

    L Gossec;J S Smolen;C Gaujoux-Viala;Z Ash

  • Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis

    Jasper J. Haringman;Danielle M. Gerlag;Aeilko H. Zwinderman;Tom J.M. Smeets

  • The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis.

    Paul Peter Tak;Barry Bresnihan

  • EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis

    Danielle M. Gerlag;Karim Raza;Lisa G M van Baarsen;Elisabeth Brouwer

  • The resolution of inflammation.

    Christopher D. Buckley;Derek W. Gilroy;Charles N. Serhan;Brigitta Stockinger

  • Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.

    P P Tak;P C Taylor;F C Breedveld;T J Smeets

  • Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

    Iain B. McInnes;Joachim Sieper;Juergen Braun;Paul Emery

  • Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides.

    I M van der Heijden;B Wilbrink;I Tchetverikov;I A Schrijver

Frequent Co-Authors

Danielle M. Gerlag
Danielle M. Gerlag UCB Pharma (United Kingdom)
Dominique Baeten
Dominique Baeten University of Amsterdam
Ferdinand C. Breedveld
Ferdinand C. Breedveld Leiden University Medical Center
Paul Emery
Paul Emery University of Leeds
Tom W. J. Huizinga
Tom W. J. Huizinga Leiden University Medical Center
Robert M. Plenge
Robert M. Plenge Bristol Myers Squibb
Lars Klareskog
Lars Klareskog Karolinska Institute
Gary S. Firestein
Gary S. Firestein University of California, San Diego
Soumya Raychaudhuri
Soumya Raychaudhuri Brigham and Women's Hospital
Frank Baas
Frank Baas Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare fields like nursing offer dynamic career paths. Many students are attracted to accelerated formats such as the 12-month accelerated nursing programs, which allow for quicker entry into the workforce without sacrificing education quality.

For beginners or those seeking a more accessible nursing route, there are lpn programs easy to get into that provide foundational knowledge and hands-on experience. These programs can serve as stepping stones toward advanced practice.

If advancing further is the goal, exploring which nurse practitioner program is easiest can help balance workload and learning speed. Such programs cater to professionals aiming for specialized roles in healthcare.

For those drawn to mental health aspects of immunology and healthcare, the top pmhnp programs offer excellent clinical placements and prepare students for impactful psychiatric-mental health nursing careers.

Best Scientists Citing Paul P. Tak

Trending Scientists

Recently Published Articles